Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi ...

These pivotal studies investigated AstraZeneca and Daiichi Sankyo’s Enhertu, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate with a topoisomerase II-targeting ...

Daiichi Sankyo stock fell 4.5% on Friday after the Japanese pharmaceutical company maintained its core operating profit target at ¥350 billion despite strong sale ...

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Friday said they began new phase 3 clinical trial testing of an intravenous treatment for advanced lung cancer.

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...

The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based ...

Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...

A new study shows children and young people faced long-lasting and higher risks of rare heart and inflammatory complications after COVID-19 infection, compared to before or without an infection.